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BACKGROUND: Antenatal steroids are standard of care for women phosphate 0.125 mg/kg, betamethasone-acetate 0.125 mg/kg, or
who are at risk of preterm delivery; however, antenatal steroid dosing and
formulation have not been evaluated adequately. The standard clinical 2-
dose treatment with betamethasone-acetateþbetamethasone-phosphate
is more effective than 2 doses of betamethasone-phosphate for the in-
duction of lung maturation in preterm fetal sheep. We hypothesized that
the slowly released betamethasone-acetate component induces similar
lung maturation to betamethasone-phosphateþbetamethasone-acetate
with decreased dose and fetal exposure.
OBJECTIVE: The purpose of this study was to investigate pharmaco-
kinetics and fetal lung maturation of antenatal betamethasone-acetate in
preterm fetal sheep.
STUDY DESIGN: Groups of 10 singleton-pregnant ewes received 1 or
2 intramuscular doses 24 hours apart of 0.25 mg/kg/dose of
betamethasone-phosphateþbetamethasone-acetate (the standard of
care dose) or 1 intramuscular dose of 0.5 mg/kg, 0.25 mg/kg, or 0.125
mg/kg of betamethasone-acetate. Fetuses were delivered 48 hours after
the first injection at 122 days of gestation (80% of term) and ventilated for
30 minutes, with ventilator settings, compliance, vital signs, and blood gas
measurements recorded every 10 minutes. After ventilation, we measured
static lung pressure-volume curves and sampled the lungs for messenger
RNA measurements. Other groups of pregnant ewes and fetuses were
catheterized and treated with intramuscular injections of betamethasone-Cite this article as: Schmidt AF, Kemp MW, Ritten-
schober-Bo¨hm J, et al. Low-dose betamethasone-
acetate for fetal lung maturation in preterm sheep. Am J
Obstet Gynecol 2018;218:132.e1-9.
0002-9378
ª 2017 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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132.e1 American Journal of Obstetrics& Gynecology JANUARY 2018betamethasone-acetate 0.5 mg/kg. Maternal and fetal betamethasone
concentrations in plasma were measured for 24 hours.
RESULTS: All betamethasone-treated groups had increased messenger
RNA expression of surfactant proteins A, B, and C, ATP-binding cassette
subfamily A member 3, and aquaporin-5 compared with control animals.
Treatment with 1 dose of intramuscular betamethasone-acetate
0.125mg/kg improved dynamic and static lung compliance, gas ex-
change, and ventilation efficiency similarly to the standard treatment of
2 doses of 0.25 m/kg of betamethasone-acetateþbetamethasone-
phosphate. Betamethasone-acetate 0.125 mg/kg resulted in lower
maternal and fetal peak plasma concentrations and decreased fetal
exposure to betamethasone compared with betamethasone-phosphate
0.125 mg/kg.
CONCLUSION: A single dose of betamethasone-acetate results in
similar fetal lung maturation as the 2-dose clinical formulation of
betamethasone-phosphateþbetamethasone-acetate with decreased fetal
exposure to betamethasone. A lower dose of betamethasone-acetate may
be an effective alternative to induce fetal lung maturation with less risk to
the fetus.
Key words: antenatal corticosteroids, betamethasone, fetal lung
maturation, prematurityntenatal corticosteroids (ANS) areA a life-saving therapy for premature
infants. Despite the well-documented
effectiveness and widespread use, ques-
tions remain regarding formulation,
dosing, route of administration, and
repeated doses1 because the ANS used
for fetal lung maturation has not been
evaluated rigorously.2 In fact, multiple
treatments are used around the world
based on drug availability and historical
use without experimental or clinicalevaluation.3 The most commonly rec-
ommended and tested regimens are
intramuscular dexamethasone-
phosphate 6 mg every 6 hours for 4
doses (total dose 24 mg) or the combi-
nation of betamethasone-acetate (Beta-
Ac) and betamethasone-phosphate
(Beta-P) 12 mg every 24 hours for 2
doses.4-6 The maturational effects of
ANS likely are determined by the length
and amplitude of fetal exposure.
Although several formulations are used
interchangeably, the pharmacokinetics
profiles of the formulations are different
and may not all be equally effective.
The 2-dose regimen of Beta-AcþBeta-
P was used by Liggins and Howie7 in
their seminal trial and has been adopted
as the standard therapy for most ran-
domized controlled trials.8 The Beta-P
component is dephosphorylated rapidly
to the active drug, which, in the sheepmodel, results in an early maternal peak
concentration of approximately 130 ng/
mL at <1 hour, with a half-life of 4
hours.9,10 The microparticulate Beta-Ac
component is slowly deacetylated,
which results in a later peak and more
prolonged half-life compared with the
phosphate component. The clinical
combination of the 2 drugs results in a
complex pharmacokinetics with a half-
life of 14 hours.10 Drug levels in
humans are limited to paired maternal
and cord blood fetal samples that are
collected from deliveries shortly after an
ANS treatment. An estimate of the initial
half-life in maternal plasma was 9 hours
with peak maternal levels of betame-
thasone at 3e4 hours of approximately
60 ng/mL and fetal plasma beta levels of
approximately 30% of maternal levels.11
In contrast, in preterm sheep a single
Beta-Ac dose of 0.25 mg/kg promotes
FIGURE 1
Experimental design
Negative control animals were treated with intramuscular saline solution. A group of animals was
treated with the clinically used formulation of Betamethasone-acetateþ Betamethasone-phosphate
as either 2 doses of 0.25 mg/kg 24 hours apart (clinical dose) or a single dose (50% total clinical
dose). Another group of animals was treated with Betamethasone-acetate only either with a dose
equivalent to the full clinical dose (0.5 mg/kg), 50% of the clinical dose (0.25 mg/kg), or 25% of the
clinical dose (0.125 mg/kg).
Beta-AcþBeta-P, betamethasone-acetateþbetamethasone-phosphate.
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level of approximately 2 ng/mL at 24
hours.9
The preterm sheep model has been
used widely for studies of fetal lung
maturation because the fetus can be
catheterized, the gestation length is
appropriate for testing exposure to de-
livery intervals relevant to the human,
and physiological responses can be
evaluated. Using a preterm fetal lamb
model, we showed that maternal intra-
muscular Beta-AcþBeta-P was more
effective than Beta-P alone for
improving lung compliance and
increased expression of surfactant pro-
tein mRNA.12 Low-dose maternal in-
fusions of Beta-P in catheterized
pregnant sheep also increased expression
of fetal lung maturation markers, despite
much lower fetal maximal concentra-
tions than the Beta-AcþBeta-P that is
used clinically.13 The pharmacokinetic
data suggest that the duration of fetal
exposure to a low plasma level of corti-
costeroids may promote fetal lung
maturation better than shorter expo-
sures to the higher plasma
concentrations.
Hence, considering the pharmacoki-
netic profile of Beta-Ac, we hypothesized
that a single lower dose of Beta-Ac would
promote lung maturation comparable
with the standard treatment with lower
fetal exposure. Clinical studies of drugand dosage are impractical for either
pharmacokinetic or pharmacodynamic
assessments of new treatment strategies.
Therefore, we tested 3 doses of Beta-Ac
that were equivalent to the full, one-
half, and one-quarter of the total Beta-
AcþBeta-P dose in preterm fetal and
newborn lamb models as an initial
strategy to refine a treatment strategy for
clinical evaluation.
Methods
Animal studies
The protocols were approved by the
animal ethics committee of The Uni-
versity of Western Australia (RA/3/100/
1378). We used chronically catheterized
pregnant sheep and their fetuses for drug
level measurements and separate pre-
term ventilated lambs to assess fetal lung
maturation after maternal ANS treat-
ment. To reduce the risk of preterm labor
from ANS, time-mated ewes with
singleton fetuses were treated with 1
intramuscular dose of 150-mg medrox-
yprogesterone acetate (Depo-Provera;
Pfizer, New York, NY) at 110 days of
gestation for pharmacokinetics studies
and at 115 days of gestation for phar-
macodynamics studies. No other doses
of medroxyprogesterone acetate were
given, and we did not administer other
tocolytics.
For pharmacodynamics studies, ani-
mals were randomized to receive eitherJANUARY 2018 Amerisaline solution (control animals) or 1 of
the following treatments: 2 doses of
Beta-AcþBeta-P (Celestone Chro-
nodose; gift from Merck Shar & Dohm
Corp., Inc, Kenilworth, NJ) 0.25 mg/kg
intramuscularly 24 hours apart, 1 dose of
Beta-AcþBeta-P of 0.25 mg/kg intra-
muscularly, 1 dose of Beta-Ac 0.5 mg/kg
intramuscularly, 1 dose of Beta-Ac 0.25
mg/kg intramuscularly, or 1 dose of
Beta-Ac 0.125 mg/kg intramuscularly
(Figure 1). The Beta-Ac was a gift from
Merck Sharp & Dohme Corp. as a
preparation of Beta-Ac that is equivalent
to that in Celestone; a 0.25-mg/kg dose
approximates the clinical dose of 12 mg
of betamethasone for a 50 kg woman and
was the same dose used for our previous
studies.9,14
For delivery, pregnant ewes were
anesthetized with intravenous mid-
azolam (0.5 mg/kg) and ketamine (10
mg/kg), followed by spinal anesthesia
with 3 mL of 2% (20 mg/mL) lidocaine
48 hours after the first intramuscular
treatment injection between 121 and 123
days of gestation. The head of the fetus
was exposed through abdominal and
uterine incisions; the fetal skin was
infiltrated with lidocaine, and a trache-
ostomywas performed for insertion of an
endotracheal tube. After delivery, fetuses
were weighted, dried, and placed on a
radiant warming bed (Cozy Cot; Fisher &
Paykel Healthcare, Auckland, New Zea-
land) and covered with a plastic wrap for
temperature control (Neowrap; Fisher &
Paykel Healthcare) for ventilation.
Mechanical ventilation
Mechanical ventilation (Fabian HFO;
Accutronic Medical Systems AG, Hirzel,
Switzerland) was started immediately
with the intermittent positive pressure
ventilation mode with standardized set-
tings: initial peak inspiratory pressure
(PIP) of 40 cm H2O, positive end expi-
ratory pressure of 5 cm H2O, respiratory
rate of 50 breaths perminute, inspiratory
time of 0.5 seconds, and 100% heated
and humidified oxygen. Animals were
kept sedated with intramuscular keta-
mine to avoid spontaneous breathing.
We inserted an umbilical artery catheter
for blood sampling. Tidal volume (Vt)
was measured continuously and keptcan Journal of Obstetrics& Gynecology 132.e2
TABLE 1
Summary of animal data for ventilation study
Variable Control
Betamethasone-
acetatecþbetamethasone-
phosphate Betamethasone-acetate1
0.25 mg/kg 2 0.25 mg/kg 1 0.5 mg/kg 0.25 mg/kg 0.125 mg/kg
Animals, n 10 9 10 10 10 10
Gestational age, da 1220.5 1220.7 1220.7 1220.7 1220.5 1220.5
Weight, kga 2.70.2 2.50.3 2.60.3 2.80.4 2.60.3 2.70.3
Sex ratio (male/female), n 8/2 6/3 6/4 4/6 6/4 7/3
Cord blood gasa
pH 7.340.03 7.340.07 7.330.05 7.280.14 7.340.02 7.350.04
pCO2 (mm Hg) 513 515 505 5921.2 473.5 514.2
pO2 (mm Hg) 182 172 183 152.4 162.7 172.7
a Data are given as meanstandard deviation.
Schmidt et al. Betamethasone-acetate for fetal lung maturation. Am J Obstet Gynecol 2018.
Original Research OBSTETRICS ajog.orgbetween 8.5 and 9.5 mL/kg by adjust-
ment of the positive inspiratory pressure
only, but with the maximal pressure
limited to 40 cm H2O. We measured
temperature, blood pressure, ventilator
data (PIP, Vt, and compliance), and
performed blood gas measurements at
10, 20, and 30 minutes of ventilation.
Dynamic compliance was recorded from
the ventilator. The ventilation efficiency
index, an integrated assessment of
ventilation and gas exchange, was
calculated with the use of the formula
ventilation efficiency index ¼ 3800/
respiratory rate (PIPepositive end
expiratory pressure) Pco2 (mmHg).15FIGURE 2
Blood gas measurements
Blood gas measurements at 30 minutes of ventila
increased pO2. The asterisk indicates a probability
Beta-AcþBeta-P, betamethasone-acetateþbetamethasone-phosph
Schmidt et al. Betamethasone-acetate for fetal lung maturation
132.e3 American Journal of Obstetrics& GynecolAfter 30 minutes of ventilation, lambs
were disconnected from the ventilator,
and the endotracheal tube was clamped
for 2 minutes to achieve complete atel-
ectasis by oxygen absorption. Lambs
were euthanized with pentobarbital and
weighed; the chest was opened for visual
evaluation of gross lung injury as pul-
monary hemorrhage, pulmonary inter-
stitial emphysema, gas pockets within
the lung, or subpleural dissection of gas.
A pressure-volume curve was measured
with air inflation of the lungs to a pres-
sure of 40 cm H2O followed by defla-
tion.9 Lung samples were snap frozen for
molecular analysis.tion of preterm lambs. Betamethasone at all dose
value of <.05.
ate.
. Am J Obstet Gynecol 2018.
ogy JANUARY 2018Messenger RNA quantitation by
quantitative polymerase chain
reaction
Frozen lung samples were homogenized,
and total RNA was isolated with TRIzol
(Invitrogen, Carlsbad, CA). Reverse
transcription was performed with the
Verso cDNA kit (Thermo Scientific,
Waltham, MA) to produce single-strand
complementary DNA. Amplification
was performed with sheep-specific
primers with Taqman probes (Applied
Biosystems, Foster City, CA) for the
following genes that are associated with
fetal lung maturation: surfactant protein
A (SFTPA), surfactant protein Bs A, increased pH, B, decreased pCO2, and C,
FIGURE 3
Ventilatory and lung mechanics variables
Ventilatory and lung mechanics variables at 30 minutes of ventilation. A, Dynamic compliance; B,
ventilatory efficiency index; C, positive inspiratory pressure; D, tidal volume. Any dose of
betamethasone-acetate, which included the lowest dosage of 0.125 mg/kg, improved all mea-
surements compared with control animals. The asterisk indicates a probability value of <.05.
Beta-AcþBeta-P, betamethasone-acetateþbetamethasone-phosphate; PIP, positive inspiratory pressure; VEI, ventilator efficiency
index; Vt, tidal volume.
Schmidt et al. Betamethasone-acetate for fetal lung maturation. Am J Obstet Gynecol 2018.
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surfactant protein D, ATP-binding
cassette subfamily A member 3
(ABCA3), and aquaporin 5 (AQP5). The
messenger RNA (mRNA) expression for
each gene was normalized to the mRNA
for the ribosomal protein 18s as internal
standard. Final data are expressed as foldFIGURE 4
Static lung compliance of exteriorized
A, Pressure volume curves; B, volume at 40 cm H
acetate. The asterisk indicates a probability value
Beta-AcþBeta-P, betamethasone-acetateþbetamethasone-phosph
Schmidt et al. Betamethasone-acetate for fetal lung maturationincrease over the mean control value for
animals that were treated with intra-
muscular saline solution.
Pharmacokinetics
For the pharmacokinetics studies, time-
mated ewes had recovery surgery for
placement of double lumen maternallungs
2O improved with any dose of Betamethasone-
of <.05.
ate; PV, pressure-volume; V40, volume at 40 cm H2O.
. Am J Obstet Gynecol 2018.
JANUARY 2018 Amerijugular and single lumen fetal jugular
catheters at 114e116 days of gestation as
described previously.16 Animals were
allowed to recover for 48 hours and then
were assigned to receive intramuscular
treatments of Beta-P 0.125 mg/kg, Beta-
Ac 0.125 mg/kg, or Beta-Ac 0.5 mg/kg.
We chose the dose of Beta-P of 0.125 mg/
kg because this is the amount of Beta-P in
a dose of Beta-PþBeta-Ac 0.25 mg/kg.
Each animal received a second intra-
muscular injection 48 hours later to allow
for drug clearance after the first treatment
and before a second injection. Maternal
and fetal blood samples of 2 mL were
collected 10minutes before and then 1, 2,
3, 4, 6, 8, 10, 12, 14, and 24 hours after
intramuscular injection into chilled
K3EDTA vacutainers. The blood was
centrifuged at 3000g, and the plasma was
frozen at e80C for betamethasone
concentration measurements. Maternal
and fetal plasma samples and betame-
thasone standards (500, 250, 100, 50, 25,
12, and 0 ng/mL) in control fetal sheep
plasma were extracted as previously
described and analyzed by mass spec-
trometry.13 The limit of the detection of
this assay is 1 ng/mL, and a cutoff >30%
of the limit was used as a zero point for
analysis. Data were fitted to a
1-compartment model with PKSolver.
All R2 values for calibration curves were
>0.98.
Statistical analysis
Data are presented as bar graphs of the
mean and standard deviations with
discrete data points for each animal.
Sample sizes were calculated with the use
of our previous data in which control
animals had amean V40 of 8mL/kg with
a standard deviation of 3.5 and in which
treated animals had a mean V40 of 16
mL/kg. With alpha set at .05 and power
of 0.8, the sample size that was needed to
identify differences between groups was
8. Considering loss of animals because of
preterm labor, we planned for 10 ani-
mals per group. Statistical tests were
performed with Prism software
(GraphPad Software Inc, San Diego,
CA). Initial comparisons were per-
formed with analysis of variance, fol-
lowed by multiple groups’ comparison
with Holm-Sidak’s post-hoc test tocan Journal of Obstetrics& Gynecology 132.e4
FIGURE 5
Messenger RNA quantitation in fold change relative to control animals
A, surfactant protein A; B, surfactant protein B; C, surfactant protein C; D, ATP-binding cassette family A member 3; E, Aquaporin 5; F, Sodium channel
epithelium 1 gamma subunit. The asterisk indicates a probability value of <.05. Single intramuscular dose of Beta-Ac increased the expression of
surfactant proteins A, B, and C, ATP-binding cassette family A member 3, and Aquaporin 5. Surfactant protein D and sodium channel epithelium 1
gamma subunit expression were not changed by any treatment.
ABCA3, ATP-binding cassette family A member 3; AQP5, Aquaporin 5; Beta-Ac, Betamethasone-acetate; Beta-AcþBeta-P, betamethasone-acetateþbetamethasone-phosphate; mRNA, messenger RNA;
SCNN1G, sodium channel epithelium 1 gamma subunit; SFTPA, surfactant protein; SFTPB, surfactant protein B; SFTPC, surfactant protein C.
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ment group, and the standard treatment
(Beta-AcþBeta-P 0.25 mg/kg  2) vs
other treatment groups. Significance was
attributed for probability values <.05.
Results
Fifty-nine animals completed the pro-
tocols. One animal in the Beta-AcþBeta-
P group was excluded because of illness
and preterm labor before receiving any
treatment. No animals had signs of pre-
term labor after ANS treatment. Groups
had similar baseline characteristics that
included gestational age, sex distribu-
tion, birthweight, and cord blood gas
values (Table 1). Vital signs did not
significantly differ after 30 minutes of
ventilation (data not shown).
Assessment of lung function
After 30 minutes of ventilation, treat-
ment with any ANS dose improved
blood gas measurements and dynamic
lung compliance relative to control ani-
mals (Figures 2 and 3). The dynamic132.e5 American Journal of Obstetrics& Gynecolcompliance increased from amean of 0.2
 0.06 in control animals to 0.5  0.15
for treated animals (P<.01). ANS treat-
ment also improved ventilation effi-
ciency index that showed better gas
exchange compared with control ani-
mals, except for the group that was
treated with 1 dose of Beta-AcþBeta-P in
which the difference was not statistically
significant (unadjusted P¼ .03; adjusted
for multiple comparisons P¼.052). At 30
minutes, the PIP was lower in animals
that were treated with Beta-AcþBeta-P
0.25 mg/kg  2, Beta-Ac 0.5 mg/kg or
0.25mg/kg compared with control ani-
mals, with the PIP that was required by
the Beta-AcþBeta-P 0.25 mg/kg  2
being significantly lower compared with
other treatment groups (P<.01;
Figure 3). It is important to note that all
animals in the control group required
the maximal PIP of 40 cm H2O, which
was not sufficient to achieve the target
Vt. All ANS treatment groups had similar
Vt means at 30 minutes. Treatment with
ANS also significantly improved staticogy JANUARY 2018lung compliance compared with control
animals as demonstrated by the
pressure-volume curves and volume at
40 cm H2O (P<.01), except for animals
that were treated with Beta-AcþBeta-P
0.25 mg/kg  1 (Figure 4). Gross lung
injury was present in 3 animals (30%) in
the control group, 1 animal (11%) in the
Beta-AcþBeta-P x 2 group, 4 animals
(40%) in the Beta-AcþBeta-P  1
group, 2 animals (20%) in Beta-Ac 0.5
mg/kg group, 2 animals (20%) in Beta-
Ac 0.25 mg/kg group, and 1 animal
(10%) in Beta-Ac 0.125 mg/kg group.
The frequency of gross lung injury was
statistically similar in treatment groups
compared with control animals.
MRNA quantitation of lung
maturation markers
All ANS treatments increased mRNA
expression of SFTPA, SFTPB, SFTPC,
ABCA3, and AQP5, compared with
control animals (Figure 5). Both the 1-
dose Beta-AcþBeta-P and the Beta-Ac
0.125 mg/kg treatments resulted in
FIGURE 6
Average plasma concentrations of betamethasone after maternal
intramuscular administration of antenatal steroids
A, Maternal (closed circle) and fetal (closed square) plasma concentrations of betamethasone after
0.5 mg/kg of betamethasone-acetate had a maternal peak concentration of 57 ng/mL at 4 hours and
fetal peak concentration of 6 ng/mL at 8 hours. B, Maternal (closed circle) and fetal (closed square)
plasma concentration of betamethasone after 0.125 mg/kg of betamethasone-acetate had a
maternal peak concentration of 27.6 ng/mL at 5.6 hours and fetal peak concentration of 3.1 ng/mL
at 8.5 hours after intramuscular injection. C,Maternal (closed circle) and fetal (closed square) plasma
concentrations of betamethasone after 0.125 mg/kg of betamethasone-phosphate had a maternal
peak concentration of 102 ng/mL at <1 hour and fetal peak concentration 11 ng/mL at 2.4 hours
after intramuscular injection. D, Comparison of fetal plasma concentrations for intramuscular
betamethasone-phosphate 0.125 mg/kg (close diamond), betamethasone-acetate 0.5 mg/kg (open
circle), and betamethasone-acetate 0.125 mg/kg (open square) had a lower peak fetal concentration
for a similar total dose of antenatal steroids after intramuscular betamethasone-acetate compared
with betamethasone-phosphate (3.1 vs 11, respectively; P<.05) and lower total fetal exposure
measured by the area under the curve.
Beta-Ac, betamethasone-acetate; Beta-P, betamethasone-phosphate.
Schmidt et al. Betamethasone-acetate for fetal lung maturation. Am J Obstet Gynecol 2018.
ajog.org OBSTETRICS Original Researchlower mRNA quantity of SFTPB,
ABCA3, and AQP5, compared with the 2
doses of Beta-AcþBeta-P 0.25 mg/kg.
Compared with the 1-dose Beta-
AcþBeta-P, the Beta-Ac 0.125 mg/kg
treatment had lower mRNA quantity of
SFTPA (P¼.01), SFTPB (p<.01), ABCA3
(P<.01), and AQP5 (P¼.03). There were
no differences between the 1-dose Beta-
AcþBeta-P and Beta-Ac 0.25 mg/kg or
0.5 mg/kg. ANS treatment did not in-
crease mRNA expression of SFPTD or
sodium channel epithelium 1 gamma
subunit.Pharmacokinetics
Free betamethasone was detected in
maternal and fetal plasma after Beta-Ac
injections for the 24 hours, except for 1
fetus. After intramuscular Beta-P, beta-
methasone was not detected (<1 ng/mL)
in the maternal plasma at 24 hours in 3
of 5 ewes and in none of the fetuses. In 2
of the 4 fetuses, betamethasone was not
detected at and after 10 hours after the
Beta-P injection. For a similar total dose
of 0.125 mg/kg, Beta-Ac resulted in
lowermaximal maternal (27.6 vs 102 ng/
mL) and fetal (3.1 vs 9.3 ng/mL)JANUARY 2018 Americoncentrations and total fetal exposure
(area under the curve, 56 vs 78 ng/
mLh) than Beta-P (P¼.04; Figure 6 and
Table 2). The fetal concentration was
approximately 10% of the maternal
concentration for the 3 treatments. Total
fetal exposure to ANS, which was
measured by the area under the curve,
was lower in Beta-Ac compared with a
similar dose of Beta-P.
A 4-fold increase in the administered
dose of intramuscular Beta-Ac, from
0.125e0.5 mg/kg resulted in approxi-
mately a 2-fold increase in the mean
maximal maternal and fetal concentra-
tion (maximum serum concentration,
27.6 vs 57.4 and 3.1 vs 6 mg/mL, respec-
tively) and in the total fetal and maternal
exposure (area under the curve, 443 vs
941 and 56 vs 104 ng/mLh, respectively).
Comment
We demonstrate that a single weight-
based maternal dose of intramuscular
Beta-Ac effectively induces physiologic
and biochemical fetal lung maturation at
lower doses than the standard of care
treatment with Beta-AcþBeta-P. The
Beta-Ac results in decreased fetal expo-
sure to corticosteroids compared with
the Beta-P component of the clinically
used combination. Corticosteroid
toxicity in general results from high dose
and long-term exposures, primarily
when used for control animals of
inclammation. The indication with ANS
is for maturational signaling, which re-
sults from a prolonged (<24 h) low
plasma level fetal exposure that can be
achieved with Beta-Ac alone, which
avoids the 2 high peak exposures from
Beta-P. The other commonly used
treatment of 4 doses of 6 mg of
dexamethasone-phosphate will expose
to fetus to 4 unnecessary high concen-
tration exposures to dexamethasone.17
There have been no short-term
adverse effects of ANS identified by
metaanalysis of the randomized
controlled trials, except for an increase in
hypoglycemia from ANS exposure in
infants who were delivered between 34
and 37 weeks.18 However, most trials
were performed in high-income coun-
tries with availability of neonatal inten-
sive care. A multicenter randomized trialcan Journal of Obstetrics& Gynecology 132.e6
TABLE 2
Pharmacokinetic measurements of maternal and fetal plasma betamethasone after intramuscular injections of
beta-phosphate or beta-acetate
Measurement
Maternal Fetal
Beta-phosphate Beta-acetate Beta-phosphate Beta-acetate
0.125 mg/kg 0.125 mg/kg 0.5 mg/kg 0.125 mg/kg 0.125 mg/kg 0.5 mg/kg
Half-life, h 2.4 9.2 11.9 5.1 6.2 6
Time of maximal concentration, h 0.87 5.6 4 2.4 8.5 7.9
Maximum serum concentration, ng/mL 102 27.6 57.4 9.3 3.1 6
Area under the curve 0-t, ng/mLh 557 443 941 78 56 104
0-t, area under the curve from time 0 the the last time measured.
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found that ANS not only did not
decrease mortality rates for infants who
were born with a birthweight <5th
percentile but it also increased neonatal
mortality rates for all infants who were
exposed to ANS prenatally, which could
not be attributed to other components of
the treatment intervention.19,20
There remain concerns for long-term
side-effects from fetal exposure to glu-
cocorticoids, particularly neurologic,
metabolic, and cardiovascular changes in
later life.21-23 A limitation to the under-
standing the long-term effects is limited
data from randomized trials. The orig-
inal trials on ANS included preterm in-
fants that were larger and of a more
advanced gestational age than the cur-
rent population of preterm infants.4 In a
30-year follow-up of former preterm
infants who were included in a ran-
domized clinical trial of ANS, Dalziel
et al24 found increased insulin levels in
glucose tolerance tests among subjects
who were exposed to prenatal betame-
thasone, which suggests modulation of
insulin sensitivity by ANS.
Because very preterm infants have a
survival benefit with ANS, it would be
unethical to perform new trials to assess
for long-term outcomes in this popula-
tion. Hence, observational studies have
attempted to address potential side-
effects of ANS. Very preterm newborn
infants who were exposed to betame-
thasone have lower birthweights, lengths,
and head circumferences than matched
term-born control infants or infants who132.e7 American Journal of Obstetrics& Gynecolwere exposed to preterm labor but not
treated with ANS who were born at
term.25,26 ANS also affects neonatal basal
cortisol levels and response to stress. In
the neonatal period, prenatal exposure to
multiple courses of ANS are associated
with lower cortisol levels at baseline and
after stress compared with single cour-
ses.27,28 At school age, a history of pre-
natal exposure to a single course of
betamethasone was associated with
increased cortisol response to a stress
compared with control infants.22 Similar
effects of ANS on fetal growth and long-
term metabolism have been reported in
multiple experimental studies of fetal
exposure to glucocorticoids; other in-
vestigators have found no or beneficial
effects of ANS.29-31 Given these concerns,
dosing optimization with minimization
of fetal exposure could prevent or
decrease long-term side-effects. These
varied observations are not based on
randomized populations.
There has been no optimization of ANS
for fetal lung maturation. A Cochrane
review compared maternal and neonatal
outcomes with different treatments and
found no differences in neonatal respira-
tory outcomes.3 This metaanalysis
included 12 clinical trials with 7 different
treatment strategies, which underscored
the wide variation in practice. A ran-
domized controlled trial is a costly and
imprecise way to test drug doses. The
preterm lamb model can be used as an
excellent translational model to test drug
dosing as preterm fetal lung maturation
and neonatal ventilation because of theogy JANUARY 2018similarities in fetal lung development be-
tween sheep and humans. Fetal sheep are
also used extensively to study maternal-
fetal interactions because of the ability to
place chronic maternal and fetal cathe-
ters.32,33 Limitation of the model is the
inability to directly assess ANS effects on
other neonatal complications such as
necrotizing enterocolitis, intraventricular
hemorrhage, or long-term outcome. In
this study, a single dose of 0.125 mg/kg of
Beta-Ac resulted in similar improvements
in lung compliance, ventilation efficiency,
and gas exchange as the clinically used
Beta-AcþBeta-P regimen, with decreased
fetal exposure to corticosteroids. Even
though the PIP at 30 minutes was not
significantly different for the lowest dose
of Beta-Ac compared with control ani-
mals, this may have resulted from the
limiting of the PIP to avoid air leaks. Only
4 animals in the Beta-Ac 0.125 mg/kg
group required the maximal PIP of 40 cm
H2O with Vt range of 5.8e7.5 mL/kg
among those animals; all animals in the
control animals group required the
maximal PIP with a Vt range of 3.1e6.4
mL/kg (mean, 4.6 mL/kg). Both dynamic
and static lung compliancewere improved
in the animals that were treatedwith Beta-
Ac 0.125 mg/kg and were similar to the
standard dosing. A dose <0.125 mg/kg
should be tested for efficacy.
The lowest Beta-Ac dosing also
increased mRNA expression levels of
surfactant proteins A, B, and C, ABCA3,
and AQP5 compared with control ani-
mals. The mRNA expression of surfac-
tant proteins A and B, ABCA3, and
ajog.org OBSTETRICS Original ResearchAQP5 was significantly higher in the
animals that received 2 doses Beta-
AcþBeta-P, compared with the lowest
dose of Beta-Ac. We did not perform
protein concentration measurements
because protein differences will not
occur until 4e5 days after ANS admin-
istration in previous studies.34 Given
that these 2 groups had similar lung
compliance and gas exchange, this dif-
ference may not be biologically relevant.
The pharmacokinetic findings
regarding peak concentrations, half-life,
and maternal-fetal transfer are in accor-
dance with previous pharmacologic
studies.9,10,13 Given that the Beta-Ac
component is only available commer-
cially in combination with Beta-P, the
pharmacologic properties of Beta-Ac
alone have not been explored thor-
oughly. Jobe et al9 previously reported
the pharmacokinetics of the 0.25 mg/kg
of Beta-Ac alone in 3 pregnant sheep. In
our study, a single 0.125-mg/kg intra-
muscular dose of Beta-Ac improved lung
mechanics and gas exchange to levels
similar to the standard 2-dose regimen
of Beta-AcþBeta-P, which provides 0.25
mg/kg of Beta-P and 0.25 mg/kg of Beta-
Ac. Maternal exposure was also reduced
significantly with Beta-Ac compared
with Beta-P. The Australasian Random-
ized Trial to Evaluate the Role of
Maternal Intramuscular Dexamethasone
trial35 currently is comparing 2 doses
given 24 hours apart of 12 mg of Beta-
AcþBeta-P to 2 doses of 12 mg of
dexamethasone-phosphate, which will
yield even higher fetal plasma dexa-
methasone exposures. The results of this
trial will provide more information on
the differences between treatments.
Considering the possible long-term
effects of ANS to the fetus, optimization
of the dose with minimization of expo-
sure is desirable. These concerns are
amplified if ANS becomes used more
widely for women who are at risk of
preterm delivery in low resource envi-
ronments, for previable fetuses who are at
risk of preterm delivery, for women who
deliver between 34 and 37 weeks gesta-
tional age, and for womenwho deliver by
elective cesarean delivery at term.18,36,37
We demonstrate that a single dose of
Beta-Ac may be an effective alternative topromote fetal lung maturation in women
who are at risk of preterm delivery while
minimizing maternal and fetal exposure
to corticosteroids. These experimental
evaluations of ANS provide a pathway to
the clinical testing of new dosing strate-
gies for ANS. nReferences
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